<DOC>
	<DOCNO>NCT00148668</DOCNO>
	<brief_summary>The purpose study find effect preoperative combination therapy herceptin/navelbine herceptin/taxotere/carboplatin patient early stage HER-2 positive breast cancer .</brief_summary>
	<brief_title>Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin HER-2 Positive Breast Cancer</brief_title>
	<detailed_description>Before start treatment , clip place via catheter tumor bed , surgeon locate site tumor . During clip placement , tissue biopsy take tumor . One two week first dose herceptin another biopsy perform . Patients place one 2 arm . - Arm 1 receives 12 week herceptin navelbine . Arm 2 receives 4 cycle taxotere/carboplatin/herceptin . - Arm 2 participant also receive neulasta ( growth factor support ) day 2 cycle . Phase A Arm 1 one dose herceptin follow MRI affect breast second biopsy 1-2 week follow dose . Phase B Arm 1 begin week 3 end week 14 involves weekly injection herceptin navelbine . Surgery take place minimum 3 week patient last dose herceptin navelbine . Phase A Arm 2 one dose herceptin follow MRI affect breast second biopsy 1-2 week follow dose . Phase B Arm 2 begin week 3 end week 14 involve herceptin weekly , taxotere carboplatin every 3 week . Surgery take place minimum 3 week patient last dose herceptin , taxotere carboplatin . Blood test perform every 3 week pre-operative treatment every 6 month surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients stage II III breast cancer HER2 positive tumor Older 18 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status great equal 1 . ANC &gt; 1,500/mm3 Hemoglobin &gt; 9gm/dl Platelets &gt; 100,000mm3 Creatinine &lt; 2mg/dl Glucose &lt; 200mg/dl Bilirubin &lt; 1.5 x ULN Previous treatment herceptin , taxanes , doxorubicin anthracyclinetype therapy , navelbine , platinumbased therapy . Pregnant breastfeed woman Serious illness , medical psychiatric condition Uncontrolled infection Active severe cardiovascular pulmonary disease Patients leave ventricular ejection fraction &lt; 50 % Peripheral neuropathy etiology exceeds grade 1 Prior history malignancy Uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HER-2 Positive Breast Cancer</keyword>
	<keyword>herceptin</keyword>
	<keyword>navelbine</keyword>
	<keyword>taxotere</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Early stage Breast Cancer</keyword>
</DOC>